Alveolus' Aero pulmonary stent:
This article was originally published in Clinica
Executive Summary
Alveolus has received US FDA 510(k) clearance to market its Aero hybrid tracheobronchial stent for treating malignant pulmonary obstructions. Malignant pulmonary obstruction causes difficulty in breathing, a condition that often requires hospitalisation, explained the Charlotte, North Carolina firm. A stent may improve the condition while reducing a patient's hospital stay. In addition to pulmonary stents, Alveolus' current portfolio of FDA-cleared and CE-marked products include oesophageal stents, guidewires and stent sizing devices.